GLYC News and Press, GlycoMimetics Inc. From 07/12/21

ToughBuilt Industries (TBLT) -29% ToughBuilt Industries launches $40M direct offeringAerpio Pharmaceuticals (ARPO) -8%.Nova LifeStyle (NVFY) -9%.UTStarcom Holdings (UTSI) -7%.GlycoMimetics (GLYC) -6%.Digital Brands Group (DBGI) -5%. For further details see: Aerpio Pharmaceutic...

Shares of GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $2.03. So far today approximately 203,000 shares have been exchanged, as compared to an average 30-day volume of 681,000 shares. GlycoMimetics Inc. (NASDAQ:GLYC) has potential upside of 0.9% based on a curren...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare Conference. Ms. King’s presentation will take place from 2:30 to 2:55 p.m. on June 3, 2021. More information is av...

GlycoMimetics (GLYC) announces that the first patient has been dosed in an investigator-sponsored trial ((IST)) evaluating uproleselan as a prophylactic agent to reduce gastrointestinal ((GI)) toxicities associated with cell transplantation for multiple myeloma ((MM)).The trial aims to study ...

Clinicians at Washington University in St. Louis Enroll Trial’s First Patient at Siteman Cancer Center GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an invest...

GlycoMimetics is priced based on a prior Phase 3 clinical trial failure. But it had strong Phase 2 acute myeloid leukemia data. The Phase 3 AML trial is expected to complete enrollment in late 2021. For further details see: GlycoMimetics A Buy On Potential 2022 AML Data ...

Image source: The Motley Fool. GlycoMimetics Inc (NASDAQ: GLYC) Q1 2021 Earnings Call May 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: GlycoMimetics Inc (GLYC) Q1 2021 Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q1 2021 Earnings Conference Call May 3, 2021 08:30 ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Chief Financial Officer John Magnani - Chief Scientific Officer Eric Feldman - Chief Medical Officer Confer...

GlycoMimetics continues to target year-end 2021 for completing enrollment of the Company-sponsored pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Enrollment in the Phase 2 portion of the NCI-sponsored Phase 2/3 registra...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-...